NICE changes its mind on rare bile duct cancer drug from IncyteIncyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, Share XNICE changes its mind on rare bile duct cancer drug from Incytehttps://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/
